A Phase 2 Controlled Trial of a Single ProHema-CB Unit (Ex Vivo Modulated Human Cord Blood) As Part of a Double Umbilical Cord Blood Transplant Following Myeloablative or Reduced Intensity Conditioning For Patients Age 15-65 Years With Hematologic Malignancies

Trial Profile

A Phase 2 Controlled Trial of a Single ProHema-CB Unit (Ex Vivo Modulated Human Cord Blood) As Part of a Double Umbilical Cord Blood Transplant Following Myeloablative or Reduced Intensity Conditioning For Patients Age 15-65 Years With Hematologic Malignancies

Discontinued
Phase of Trial: Phase II

Latest Information Update: 25 Aug 2017

At a glance

  • Drugs FT 1050 (Primary)
  • Indications Stem cell mobilisation
  • Focus Therapeutic Use
  • Acronyms PUMA
  • Sponsors Fate Therapeutics
  • Most Recent Events

    • 11 Apr 2016 Status changed from recruiting to discontinued. Reason the study was stopped: Business decision
    • 21 Sep 2015 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov record.
    • 21 Sep 2015 Planned primary completion date changed from 1 May 2015 to 1 May 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top